Curated News
By: NewsRamp Editorial Staff
June 18, 2026
Kiora's KIO-300 Suppresses Seizure Activity in Preclinical Epilepsy Model
TLDR
- Kiora's KIO-300 shows seizure suppression, advancing its pipeline beyond vision restoration into epilepsy, potentially expanding market opportunity.
- KIO-300, an ion channel modulator, significantly reduced epileptiform activity in an ex vivo temporal lobe epilepsy model, as shown in preclinical data.
- This research offers hope for epilepsy patients by demonstrating a novel approach to suppressing seizures, potentially improving quality of life.
- KIO-300, a compound originally developed for vision restoration, unexpectedly shows promise in treating epilepsy through ion channel modulation.
Impact - Why it Matters
This news matters because epilepsy affects approximately 50 million people worldwide, and current treatments often fail to control seizures or cause significant side effects. Kiora's KIO-300, derived from a platform already in clinical trials for blindness, offers a potential new mechanism—ion channel modulation—that could lead to more effective and better-tolerated therapies. The dual application of this molecule across eye and brain disorders highlights the promise of targeted small molecules in addressing complex neurological conditions. For investors and patients, this represents a potential expansion of Kiora's pipeline into a massive unmet medical need, with early data suggesting efficacy in a key epilepsy model.
Summary
Kiora Pharmaceuticals (NASDAQ: KPRX) has unveiled promising preclinical data for its novel ion channel modulator, KIO-300, demonstrating significant suppression of seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA. KIO-300, which is the active pharmaceutical ingredient of KIO-301—Kiora’s Phase 2 candidate for vision restoration in retinitis pigmentosa—showed a marked reduction in epileptiform activity, suggesting potential as a therapeutic for epilepsy. This dual application underscores the versatility of Kiora’s ion channel modulator platform, which aims to target neurological and ophthalmic diseases through small-molecule interventions.
Kiora Pharmaceuticals is a clinical-stage biotechnology company focusing on advanced therapies for retinal disease, but this new data opens a potential pipeline into neurology. The company’s lead candidate, KIO-301, is a molecular photoswitch designed to restore vision in patients with inherited retinal degenerations, including retinitis pigmentosa, choroideremia, and Stargardt disease. Meanwhile, KIO-104 targets macular edema via a non-steroidal, immuno-modulatory mechanism. The preclinical success of KIO-300 in epilepsy models highlights the broader applicability of their technology. For more details, click here to view the full announcement.
This development is particularly significant as it demonstrates the potential for Kiora’s ion channel modulators to address multiple high-need indications beyond ophthalmology. The company’s ability to repurpose molecules across disease areas could accelerate clinical timelines and expand market opportunities. With ongoing Phase 2 trials for KIO-301 and a growing preclinical pipeline, Kiora is positioning itself as a versatile player in both neurology and ophthalmology. The data presented at the conference represent an early but encouraging step toward novel epilepsy treatments, leveraging the same ion channel modulation that underpins their vision restoration efforts.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Kiora's KIO-300 Suppresses Seizure Activity in Preclinical Epilepsy Model
